Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709109 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
A Phase 2 study, sponsored by Parion Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
NCT02709109 is a Phase 2 study that has completed, run by Parion Sciences. The registered enrollment target is 147 participants.
The verdict
NCT02709109, a Phase 2 study, has completed, sponsored by Parion Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 in hypertonic saline compared to hypertonic saline alone in subjects with cystic fibrosis (CF) who are ≥12 years of age, homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation, and being treated with Orkambi
Interventions
- DRUG Placebo
- DRUG Hypertonic saline
- DRUG VX-371 + HS
- DRUG Orkambi
- DRUG VX-371
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02709109
The ClinicalTrials.gov registry entry for NCT02709109 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Parion Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02709109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02709109 about?
NCT02709109 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation". The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 in hypertonic saline compared to hypertonic saline alone in subjects with cystic fibrosis (CF) who are ≥12 years of age, homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mut...
What is the current status of trial NCT02709109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2016-02. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02709109?
The interventions under investigation include: Placebo (DRUG), Hypertonic saline (DRUG), VX-371 + HS (DRUG), Orkambi (DRUG), VX-371 (DRUG).
Who is sponsoring clinical trial NCT02709109?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.